Abbott Laboratories

NYSE:ABT

Medical - Devices

Healthcare
$104.48 -0.58%

-$0.51 today

Market cap
$180.95B
Beta
0.62
P/E (TTM)
24.5
EPS (TTM)
$3.59
Dividend yield
2.77%
52W Low $81.97High $139.06

Volume 7.02M

Average 13.17M

ABT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Abbott LaboratoriesNYSE: ABT

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables declines year over year

Q2 FY2026 accounts receivables of $386M (cash outflow) fell 5.9% year over year, ahead of the -54.0% change in trailing-twelve-month accounts receivables. Sequentially, it rose 819.0% from the prior quarter. Over 3 fiscal years it compounded at +112.4% a year.

Context

  • Accounts receivables amounted to 1.5% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -5.9% holds above the trailing-twelve-month pace of -54.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$386M+819.0% QoQ
Last fiscal yearDec 2025
-$652M-5.6% YoY
LTMJun 2026
-$408M-54.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.9%——
1 year-5.6%——
3-year CAGR+112.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(652M) USD
Year-over-year change
+5.6%

Accounts Receivables vs competitors

How ABT compares with its peers on the latest reported figures

  • ABT's LTM Jun 2026 accounts receivables of $408M is the 2nd largest of the 10 companies compared; the peer median is $174M.
  • Its year-over-year change of -54.0% is the 8th highest of 9, against a peer median of +51.9%.
  • Accounts receivables amounts to 0.9% of revenue for ABT, versus a peer median of 0.7%.
ABT Competitors Peer median
Accounts Receivables for ABT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$1.37B +3.7%+11.4%1.4%
ABTAbbott LaboratoriesLTM Jun 2026$408M -54.0%+112.4%0.9%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$402M +166.2%-21.1%2.0%
BSXBoston Scientific CorporationLTM Jun 2026$293M +144.2%+6.9%1.4%
MDTMedtronic plcLTM Jul 2026$264M +3.5%-29.7%0.7%
DHRDanaher CorporationLTM Sep 2026$174M -19.4%-23.2%0.7%
SYKStryker CorporationLTM Jun 2026$137M +182.0%—0.5%
EWEdwards Lifesciences CorporationLTM Jun 2026$82.5M -197.5%-35.1%1.3%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$0 +100.0%-0.3%0.0%
BDXBecton, Dickinson and CompanyLTM Sep 2026$0 ——0.0%
Peer median (excluding ABT) $174M+51.9%-21.1%0.7%

Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.07B6.93B5.72B13.4B6.52B
Depreciation & Amortization3.54B3.27B3.24B3.22B3.12B
Deferred Income Tax00000
Stock-Based Compensation640M685M644M673M664M
Change in Working Capital(771M)(1.52B)(2.48B)(9.22B)(803M)
Accounts Receivables(383M)(68M)(356M)(691M)(652M)
Inventory(456M)(1.41B)(232M)(58M)195M
Accounts Payables1.29B420M(760M)356M954M
Other Working Capital(1.22B)(458M)(1.13B)(8.82B)(1.3B)
Other Non-Cash Items55M215M126M482M65M
Operating Cash Flow10.53B9.58B7.26B8.56B9.57B
Capital Expenditures(1.89B)(1.78B)(2.2B)(2.21B)(2.17B)
Acquisitions (Net)(53M)48M(837M)1M(105M)
Purchases of Investments(173M)(185M)(159M)(169M)(167M)
Sales of Investments77M152M43M28M3M
Other Investing Activities26M22M22M9M18M
Investing Cash Flow(2.01B)(1.74B)(3.13B)(2.34B)(2.42B)
Debt Repayment(248M)(699M)(2.48B)(537M)(1.61B)
Common Stock Issued0000396M
Common Stock Repurchased(2.3B)(3.8B)(1.23B)(1.3B)(893M)
Dividends Paid(3.2B)(3.31B)(3.56B)(3.84B)(4.12B)
Other Financing Activities255M167M167M264M(82M)
Financing Cash Flow(5.49B)(7.64B)(7.09B)(5.4B)(6.31B)
Effect of Forex Changes(70M)(122M)(23M)(96M)71M
Net Change in Cash2.96B83M(2.99B)720M906M
Free Cash Flow8.65B7.8B5.06B6.35B7.4B

Abbott Laboratories

NYSE:ABT

Intrinsic Alpha fair value

Locked

Current Price

$104.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.